The landscape of obesity treatment is undergoing significant transformation with the introduction and anticipated approvals of oral GLP-1 receptor agonist medications. Novo Nordisk has launched an oral formulation of its semaglutide-based weight-loss drug, Wegovy, in the United States, following FDA approval in December. This development positions Novo Nordisk ahead of rival Eli Lilly, which is awaiting FDA approval for its own oral obesity pill, orforglipron.
These daily oral treatments aim to provide a convenient alternative to existing weekly injectable medications, potentially expanding patient access and influencing drug affordability within the growing obesity management market.
Regulatory Approval and Market Introduction
Novo Nordisk's Oral Wegovy Approval
The U.S. Food and Drug Administration (FDA) granted approval for Novo Nordisk's oral semaglutide (marketed as Wegovy pill) on December 22. This marks the first FDA-approved oral medication specifically for chronic weight management in adults with obesity or those classified as overweight with at least one weight-related comorbidity. The approval also extends to reducing the risk of major adverse cardiovascular events in adults with obesity and established cardiovascular disease.
Following its approval, the Novo Nordisk oral Wegovy began its U.S. rollout on January 5, with initial doses becoming available in pharmacies and through various distribution channels. Higher doses were scheduled for subsequent availability.
The FDA's approval of Novo Nordisk's oral semaglutide on December 22 represents a landmark, making it the first oral medication specifically for chronic weight management in adults with obesity or overweight and comorbidities.
Eli Lilly's Orforglipron Status
Eli Lilly's competing oral drug, orforglipron, is currently under FDA review. Eli Lilly has indicated plans to submit orforglipron for FDA approval, potentially expediting the decision process through a priority review voucher. Anticipation for its approval ranges from early this year to mid-to-late 2026.
Product Details and Mechanism of Action
Both Novo Nordisk's oral semaglutide and Eli Lilly's orforglipron are GLP-1 receptor agonists. These medications mimic the natural gut hormone GLP-1, which plays a role in regulating appetite, promoting feelings of satiety, slowing stomach emptying, and stimulating insulin production when blood sugar is high. Tirzepatide, the active ingredient in Eli Lilly's injectable Zepbound and Mounjaro, additionally mimics the GIP hormone.
Novo Nordisk's Oral Semaglutide
- Contains semaglutide, the same active ingredient as injectable Wegovy, Ozempic, and the Type 2 diabetes pill Rybelsus, but in a higher dose for the obesity indication.
- Requires daily administration.
- Must be taken on an empty stomach with a small amount of water, followed by a 30-minute waiting period before consuming food or other beverages. This is due to an added ingredient, SNAC, which temporarily reduces stomach acidity and aids absorption.
Eli Lilly's Orforglipron
- Features a novel ingredient, orforglipron, which is distinct from its injectable tirzepatide.
- Also a daily oral medication.
- Designed as a small molecule compound with greater stability in the stomach, requiring no specific food or water restrictions for effective absorption.
Efficacy and Side Effect Profile
Clinical Efficacy
Clinical trials have provided data on the effectiveness of these oral medications:
- Novo Nordisk's Oral Semaglutide (25 mg dose): Studies indicated an average weight reduction of 16.6% over 64 weeks for patients who adhered to treatment, reduced caloric intake, and engaged in exercise. A study published in the New England Journal of Medicine reported an average weight loss of 13.6% over approximately 15 months (compared to 2.2% in a placebo group), which is comparable to the injectable version of Wegovy.
- Eli Lilly's Orforglipron (highest dose): Achieved an average weight loss of 12.4% over 72 weeks in one study, and 11.2% over nearly 17 months in another (versus 2.1% in the placebo group). This efficacy is reported to be lower than that observed with Eli Lilly's injectable Zepbound, which targets both GLP-1 and GIP hormones.
Common Side Effects
Both oral drugs share similar side effects with their injectable counterparts, including nausea, diarrhea, vomiting, constipation, and abdominal pain. Other potential side effects can include muscle loss and gallbladder problems. Patients are advised that weight regain is common upon discontinuation of GLP-1 medication.
While effective, patients using GLP-1 medications should be aware that weight regain is common upon discontinuation of treatment.
Cost, Affordability, and Access
Oral medications generally have lower manufacturing costs than injectables, influencing their pricing and accessibility strategies.
Novo Nordisk's Oral Wegovy Pricing
- Cash prices range from $149 to $299 per month, depending on the dosage. The starting dose is priced at $149 per month.
- For insured patients, the monthly cost may be as low as $25, depending on coverage.
- The list price for the oral Wegovy matches its injectable counterpart at approximately $1,349 per month.
- An agreement established with the Trump administration allows the starting dose to be sold directly to consumers for $149 per month without requiring health insurance.
- Novo Nordisk plans to reduce the list prices of its obesity and diabetes drugs, including oral Wegovy, to $675 per month starting January 1, 2027.
Eli Lilly's Orforglipron Pricing
- Eli Lilly has indicated plans to cap higher doses at $399 per month for cash-paying patients, pending regulatory approval.
Access Challenges and Initiatives
Affordability and insurance coverage have been significant barriers to access for injectable GLP-1 drugs, which often have list prices exceeding $1,000 per month. A KFF poll indicated that one in eight individuals are using this class of injectable drugs, with over half reporting difficulties with affordability despite insurance coverage.
Efforts to enhance access include:
- Direct-to-Consumer Models: Novo Nordisk offers its oral Wegovy through various pharmacies (including CVS, Costco), telehealth providers (Ro, LifeMD, Weight Watchers, GoodRx), Amazon Pharmacy, and the TrumpRx platform.
- Employer Programs: Eli Lilly launched its "Employer Connect" program to help employers offer more flexible and discounted coverage options for obesity drugs like Zepbound, aiming for a net discounted price of $449 per month for a multi-dose form of Zepbound through participating administrators.
- Medicare Coverage: Eli Lilly's CEO anticipates Medicare coverage for obesity treatments coinciding with orforglipron's launch, which could significantly expand patient reach.
Affordability and insurance coverage have been major hurdles for injectable GLP-1s, prompting drugmakers to introduce lower-cost oral options and diverse access strategies.
Market Context and Competition
The global weight loss drug market is projected to reach approximately $100 billion by the 2030s, with oral drugs estimated to comprise about 24% of this market by 2030. The entry of oral GLP-1s intensifies competition between Novo Nordisk and Eli Lilly, which are dominant players in this sector.
Early prescription data for Novo Nordisk's oral Wegovy indicated approximately 3,100 to 4,290 prescriptions filled in its first week, predominantly for the starting dose. This volume reportedly exceeded that of Eli Lilly's injectable Zepbound during its initial launch phase, though comprehensive assessment requires more data.
Despite a strong launch for oral Wegovy, Novo Nordisk has forecasted a significant revenue decline (5% to 13%) for the current year. This is attributed to "unprecedented pricing pressure" from agreements to reduce U.S. drug prices, the expiration of semaglutide patents in some countries, and competition from compounded versions. Eli Lilly, conversely, has forecasted stronger sales and profit growth, projecting a 45% increase in sales.
Future Developments and Personalized Medicine
Both companies are actively developing next-generation compounds:
- Novo Nordisk is studying cagrilintide and a combination of cagrilintide and semaglutide.
- Eli Lilly is investigating retatrutide, a "triple G" drug mimicking GLP-1, GIP, and glucagon, which is in Phase 3 clinical trials.
- Other companies, such as Metsera (acquired by Pfizer), are also developing obesity drugs.
The future of obesity treatment is expected to shift towards personalized medicine. Researchers anticipate that within several years, treatments will be tailored by identifying individual root causes of obesity, such as specific genetic markers or obesity phenotypes ('Hungry Gut,' 'Hungry Brain,' 'Emotional Hunger,' 'Slow Burn'). This approach aims to guide more targeted interventions beyond a universal GLP-1 therapy.
Future obesity treatment is expected to move beyond universal GLP-1 therapies towards personalized medicine, tailoring interventions based on individual genetic markers and obesity phenotypes.
Concerns Regarding Misuse and Disordered Eating
The increasing availability and effectiveness of GLP-1 drugs have raised concerns regarding their appropriate use, particularly among individuals without a medical indication for obesity or those with existing or developing disordered eating patterns. Psychologists and specialists emphasize that most patients are not screened for eating disorders prior to prescription.
Key Risks Highlighted:
- Use for purely aesthetic reasons by individuals without excess weight.
- Potential for initial muscle loss and subsequent fat regain upon stopping the drug, contributing to "yo-yo dieting."
- Difficulty for some individuals to nourish themselves or recognize natural hunger cues due to the drugs' potency.
- Compounding the psychological factors of complex eating disorders, which often co-occur with mental health conditions.
- Vulnerability of "atypical anorexics" who meet criteria for anorexia but are not underweight, potentially being prescribed GLP-1s based solely on body size.
While GLP-1 drugs may assist individuals with specific eating disorders linked to lower natural GLP hormone production, medical experts urge caution and immediate intervention in cases of misuse, such as patients with severe anorexia acquiring drugs illicitly.